- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01472419
Prognostic Factor Analysis in Metastatic Esophageal Squamous Cell Carcinoma
April 7, 2013 updated by: Jeeyun Lee, Samsung Medical Center
Fluoropyrimidine/Platinum-based First-line Chemotherapy in Metastatic Esophageal Squamous Cell Carcinoma: Prognostic Factor Analysis in 239 Patients
Esophageal squamous cell carcinoma is considerably more prevalent in East Asia.
Despite of relatively high prevalence of esophageal SCC, prognosis is very poor with limited options of effective chemotherapy regimens.
We attempted to identify favorable subgroups of patient who are likely to benefit from 5- fluorouracil/cisplatin(FP) or capecitabine/cisplatin (XP) chemotherapy as first-line treatment.Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy.
Clinicopathologic variables and treatment outcome were retrospectively collected.
we analysis treatment outcome of palliative chemotherapy in metastatic esophageal squamous cell carcinoma and make prognostic scoring system.
The present study represents the largest series to analyze the treatment outcome of FP/XP chemotherapy in metastatic SCC.
Risk-adapted stratification of treatment for subgroup of metastatic SCC patients should be actively pursued.
Study Overview
Status
Completed
Study Type
Observational
Enrollment (Actual)
239
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Between January 2000 to December 2010, 239 patients were diagnosed of recurrent, metastatic esophageal SCC and received either FP or XP as first-line chemotherapy.
Description
Inclusion Criteria:
- recurrent, metastatic esophageal SCC
- received either FP or XP as first-line chemotherapy.
Exclusion Criteria:
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: 12 month
|
12 month
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
March 1, 2012
Primary Completion (Actual)
December 1, 2012
Study Completion (Actual)
March 1, 2013
Study Registration Dates
First Submitted
November 11, 2011
First Submitted That Met QC Criteria
November 15, 2011
First Posted (Estimate)
November 16, 2011
Study Record Updates
Last Update Posted (Estimate)
April 9, 2013
Last Update Submitted That Met QC Criteria
April 7, 2013
Last Verified
April 1, 2013
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Head and Neck Neoplasms
- Esophageal Diseases
- Neoplasms, Squamous Cell
- Esophageal Neoplasms
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Squamous Cell Carcinoma
Other Study ID Numbers
- SMCESOPROGNOSIS
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Esophageal Squamous Cell Carcinoma
-
National Cancer Institute (NCI)Active, not recruitingRecurrent Esophageal Carcinoma | Metastatic Gastroesophageal Junction Adenocarcinoma | Stage IV Esophageal Cancer AJCC v7 | Metastatic Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Adenocarcinoma | Recurrent Gastroesophageal Junction Adenocarcinoma | Recurrent Esophageal Adenocarcinoma and other conditionsUnited States
-
Cancer Institute and Hospital, Chinese Academy...Akeso Pharmaceuticals, Inc.Not yet recruitingMetastatic Esophageal Squamous Cell Carcinoma | Unresectable Esophageal Squamous Cell Carcinoma | Locally Advanced Esophageal Squamous Cell Carcinoma
-
Shanghai Chest HospitalRecruitingEsophageal Cancer | Esophageal Squamous Cell Carcinoma | Metastatic Esophageal Squamous Cell CarcinomaChina
-
National Taiwan University HospitalEnrolling by invitationMetastatic Esophageal Squamous Cell Carcinoma | Esophageal TumorTaiwan
-
Qingdao Central HospitalRecruitingMetastatic Esophageal Squamous Cell CarcinomaChina
-
Tianjin Medical University Cancer Institute and...The First Affiliated Hospital with Nanjing Medical University; Shanxi Province... and other collaboratorsCompletedMetastatic Esophageal Squamous Cell CarcinomaChina
-
Fudan UniversityActive, not recruitingMetastatic Esophageal Squamous Cell CarcinomaChina
-
Fudan UniversityCompleted
-
Fudan UniversityRecruitingMetastatic Esophageal Squamous Cell CarcinomaChina
-
Sun Yat-sen UniversityRecruitingMetastatic Esophageal Squamous Cell CarcinomaChina